Wyeth launches major Phase IV trial of new pneumonia vaccine in the elderly
This article was originally published in Scrip
Executive Summary
WyethPharmaceuticals has announced the start of its Community Acquired Pneumonia Immunization Trial in Adults (CAPITA), a major Phase IV study investigating its investigational 13-valent conjugate vaccine, Prevenar-13, designed for the prevention of pneumococcal pneumonia – the leading cause of bacterial pneumonia in adults.